Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism

Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism

Objective: Cost-effectiveness analysis of a 6-month treatment of apixaban (10 mg/12h, first 7 days; 5 mg/12h afterwards) for the treatment of the first event of venous thromboembolism (VTE) and prevention of recurrences, versus low-molecular-weight heparins/vitamin K antagonists treatment (LMWH/VKA)...

Full description

Saved in:
Bibliographic Details
Main Authors: Isabel Elías, Itziar Oyagüez, Luis Antonio Alvarez-Sala, Fernando García-Bragadoa, Andrés Navarro, Paloma González, Fernando de Andrés-Nogales, Javier Soto
Format: Article
Language:English
Published: Elsevier 2016-05-01
Series:Farmacia Hospitalaria
Subjects:
Anticoagulants
; Apixaban
; Cost-effectiveness
Deep vein thrombosis
Pulmonary embolism
Venous
thromboembolism
Online Access:http://www.aulamedica.es/fh/pdf/10461.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.aulamedica.es/fh/pdf/10461.pdf

Similar Items